A Study of Berubicin in Adult Subjects With Recurrent Glioblastoma Multiforme
Public ClinicalTrials.gov record NCT04762069. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multicenter, Open-Label Study With a Randomized Control Arm of the Efficacy, Safety, and Pharmacokinetics of Intravenously Infused Berubicin in Adult Patients With Recurrent Glioblastoma Multiforme After Failure of Standard First Line Therapy
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is an open-label, multicenter, randomized, parallel, 2-arm, efficacy and safety study. Patients with GBM after failure of standard first line therapy will be randomized in a 2:1 ratio to receive berubicin or lomustine for the evaluation of OS. Additional endpoints will include response and progression outcomes evaluated by a blinded central reviewer for each patient according to RANO criteria. A pre-planned, non-binding futility analysis will be performed after approximately 30 to 50% of all planned patients have completed the primary endpoint at 6 months. This review will include additional evaluation of safety as well as secondary efficacy endpoints. Enrollment will not be paused during this interim analysis.
Study identification
- NCT ID
- NCT04762069
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 252 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 18, 2021 (Actual)
- Primary completion
- Apr 27, 2026 (Estimated)
- Completion
- Jul 15, 2026 (Estimated)
- Last update posted
- Apr 15, 2026
2021 – 2026
United States locations
- U.S. sites
- 32
- U.S. states
- 21
- U.S. cities
- 31
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Arkansas | Little Rock | Arkansas | 72205 | — |
| Southern California Permanente Medical Group | Los Angeles | California | 90027 | — |
| University of California Irvine | Orange | California | 92868 | — |
| University of Califonia San Diego Moores Cancer Center | San Diego | California | 92093 | — |
| University of California San Francisco | San Francisco | California | 94143 | — |
| Saint John's Cancer Institute at Providence Saint John's Health Center | Santa Monica | California | 90404 | — |
| HCA Healthcare Research Institute | Englewood | Colorado | 80113 | — |
| Baptist MD Anderson Cancer Center | Jacksonville | Florida | 32207 | — |
| Mayo Clinic Florida | Jacksonville | Florida | 32224 | — |
| Baptist Miami | Miami | Florida | 33176 | — |
| Piedmont Healthcare | Atlanta | Georgia | 30309 | — |
| Rush University Cancer Center | Chicago | Illinois | 60612 | — |
| University of Kentucky | Lexington | Kentucky | 40536 | — |
| Tulane Cancer Center Clinic | New Orleans | Louisiana | 70112 | — |
| Tufts Medical Center | Boston | Massachusetts | 02111 | — |
| UMass (ACC) - Hollings Cancer Center (HCC) | Worcester | Massachusetts | 01655 | — |
| Mayo Clinic | Rochester | Minnesota | 550905 | — |
| University of Nebraska Medical Center | Omaha | Nebraska | 68198 | — |
| Hackensack Meridian Health | Hackensack | New Jersey | 07601 | — |
| Rutgers University | Piscataway | New Jersey | 08854 | — |
| Atlantic Healthcare | Summit | New Jersey | 07901 | — |
| Roswell Park Cancer Center | Buffalo | New York | 14263 | — |
| Duke University School of Medicine | Durham | North Carolina | 27710 | — |
| Ohio State University | Columbus | Ohio | 43210 | — |
| Providence Health | Portland | Oregon | 97225 | — |
| Milton S. Hershey Medical Center | Hershey | Pennsylvania | 17033 | — |
| Texas Oncology PA | Austin | Texas | 78758 | — |
| Baylor Research Institute | Dallas | Texas | 75246 | — |
| University of Texas Health Science Center at Houston | Houston | Texas | 77027 | — |
| Huntsman Cancer Center | Salt Lake City | Utah | 84112 | — |
| Swedish Medical Center | Seattle | Washington | 98122 | — |
| University of Wisconsin Hospital and Clinics | Madison | Wisconsin | 53705 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 16 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04762069, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 15, 2026 · Synced Oct 23, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT04762069 live on ClinicalTrials.gov.